Multicentre, Open-Label Trial to Assess the Safety and Tolerability of LF111 (Drospirenone 4.0 mg) Over 6 Cycles in Female Adolescents, With a 7-Cycle Extension Phase
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2016
At a glance
- Drugs Drospirenone (Primary)
- Indications Pregnancy
- Focus Adverse reactions; Registrational
- Sponsors Leon Farma
- 15 Oct 2016 This trial was completed in Germany (end date: 2016-09-19), according to European Clinical Trials Database.
- 26 Aug 2016 This trial was completed in Sweden.
- 07 May 2016 This trial was completed in Finland according to the European Clinical Trials Database.